Simoctocog alfa

Drug Profile

Simoctocog alfa

Alternative Names: Factor VIII - Octapharma; Human-cl rhFVIII - Octapharma; Nuwiq

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Octapharma
  • Developer Cardinal Health; Octapharma
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 21 Dec 2016 Interim immunogenicity data from the phase III NuProtect presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 17 Oct 2016 Simoctocog alfa licensed to Cardinal Health in Puerto Rico
  • 17 Oct 2016 Launched for Haemophilia A (In children, In adults) in Puerto Rico (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top